Study of drug-resistant bacteria in cancer patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at cancer patients at Sohag Oncology Center who have infections caused by a specific type of hard-to-treat bacteria. It aims to understand how these bacteria become resistant to strong antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a patient at Sohag Oncology Center.
- You currently have an infection in any part of your body.
- Your infection is caused by a bacteria called Enterobacterales that is resistant to carbapenem antibiotics, as shown by a lab test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibiotic combination (ceftazidime-avibactam) for people with difficult-to-treat Klebsiella pneumoniae infections that are resistant to carbapenem antibiotics due to a specific enzyme. It may help if you have a skin, chest, surgical wound, or urinary tract infection from this resistant bacteria.
This trial looks at bacteria from hospital patients that are hard to treat because they resist many drugs, especially the antibiotic colistin. It aims to understand how these bacteria become resistant so doctors can better choose treatments.
This study looks at new ways to fight antibiotic-resistant bacteria in people with certain common infections. It may help by testing approaches tailored to the specific germs found in your urine, lungs, or deeper infections.
This study tests the best time to start powerful antibiotics in blood cancer patients who are at high risk for infection with carbapenem-resistant bacteria. It aims to improve treatment success and reduce complications.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This study looks at blood cancer patients who are carrying a certain type of antibiotic-resistant bacteria (without causing infection yet). It aims to develop a score to predict which patients might later develop an infection. If you are receiving treatment that lowers your white blood cells (neutropenia), you may be eligible.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.